Attenuation of traumatic brain injury-induced cognitive impairment in mice by targeting increased cytokine levels with a small molecule experimental therapeutic

Table 2 Effect of CHI and MW151 treatment on IBA1, CD45, and GFAP staining

IHC stain	Brain region	Sham + veh	CHI + veh	CHI + MW151
IHC stain	Brain region	( n = 11)	( n = 14)	( n = 14)
IBA1	Neocortex: focus	0.0 ± 0.2	0.3 ± 0.5	0.2 ± 0.3
	Neocortex: all	0.0 ± 0.1	0.1 ± 0.2	0.0 ± 0.2
	Hippocampus	0.0 ± 0.2	0 ± 0.2	−0.1 ± 0.1
	Corpus callosum	0.0 ± 0.5	0.1 ± 0.5	0.1 ± 0.5
	Entorhinal cortex	0.0 ± 0.2	0 ± 0.2	0.0 ± 0.2
CD45	Neocortex: focus	0.0 ± 1.3	7.7 ± 10.4	4.4 ± 5.2
	Neocortex: all	0.0 ± 1.2	2.3 ± 3.6	1.4 ± 2.5
	Hippocampus	0.0 ± 0.7	0.2 ± 0.9	0.3 ± 1.1
	Corpus callosum	0.0 ± 0.6	1.2 ± 1.1	1.3 ± 1.3
	Entorhinal cortex	0.0 ± 0.7	0.6 ± 1.0	0.9 ± 1.5
GFAP	Neocortex: focus	0.0 ± 0.3	4.6 ± 3.7	3.9 ± 3.1
	Neocortex: all	0.0 ± 0.2	1.7 ± 1.4	1.5 ± 1.3
	Hippocampus	0.0 ± 0.1	0.0 ± 0.1	0.0 ± 0.1
	Corpus callosum	0.0 ± 0.2	0.3 ± 0.3	0.4 ± 0.3
	Entorhinal cortex	0.0 ± 0.2	0.4 ± 0.3	0.4 ± 0.3

Data expressed as change from sham + veh baseline (mean ± SD). CHI, closed head injury; IHC, immunohistochemical; GFAP, glial fibrillary acidic protein; veh, vehicle.

ISSN: 1742-2094